Novartis' Certican To Get Advisory Committee Review For Heart Transplant Rejection
This article was originally published in The Pink Sheet Daily
Executive Summary
The proliferation inhibitor everolimus will be reviewed by FDA's Cardiovascular & Renal Drugs Advisory Committee on Nov. 16.
You may also be interested in...
Novartis Anticipates Diovan Pricing Will Contribute To Near-Term Growth
Pending oral iron-chelating agent Exjade could be priced at a premium compared with current first-line therapy, Novartis says during its third quarter call Oct. 18.
Novartis Anticipates Diovan Pricing Will Contribute To Near-Term Growth
Pending oral iron-chelating agent Exjade could be priced at a premium compared with current first-line therapy, Novartis says during its third quarter call Oct. 18.
Novartis' Certican Requires Further Dosing Studies, FDA "Approvable" Letter Says
The company will decide how to pursue development program for transplant agent Certican in combination with Neoral by the first week of September, Novartis says. The action letter recommends additional dosing studies of Neoral.